Shanghai Yizhong announced that the company's core product, the injectable paclitaxel polymer micelle, has obtained the “Drug Clinical Trial Approval Notice” and agreed to carry out clinical trials with new indications for pancreatic cancer. This test is an effective design test of injectable paclitaxel polymer micelles combined with gemcitabine compared with albumin paclitaxel plus gemcitabine. It aims to compare and evaluate clinical research indicators such as progression-free survival, overall survival, objective remission rate, and disease control rate of the two groups of patients.

Zhitongcaijing · 10/15 07:41
Shanghai Yizhong announced that the company's core product, the injectable paclitaxel polymer micelle, has obtained the “Drug Clinical Trial Approval Notice” and agreed to carry out clinical trials with new indications for pancreatic cancer. This test is an effective design test of injectable paclitaxel polymer micelles combined with gemcitabine compared with albumin paclitaxel plus gemcitabine. It aims to compare and evaluate clinical research indicators such as progression-free survival, overall survival, objective remission rate, and disease control rate of the two groups of patients.